APLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Apellis Pharmaceuticals Inc (APLS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral to slightly bearish, and the company's financial performance shows mixed results with declining revenue but improved net income and EPS. While there are positive catalysts such as hedge fund buying and optimism from certain analysts, the lack of significant momentum, flat pricing expectations, and limited growth projections make it prudent to hold off on buying this stock now.
The MACD is below 0 and negatively expanding, indicating bearish momentum. RSI is neutral at 39.207, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 21.645, with resistance at 22.681 and support at 20.61.
Hedge funds are significantly increasing their buying activity, up 132.99% over the last quarter.
H.C. Wainwright raised its price target to $48, citing optimism about Syfovre's long-term potential.
Apellis has $466 million in cash to fund operations until profitability.
Revenue declined 5.94% YoY in Q4 2025, and management anticipates flat Syfovre pricing into FY26 with limited growth.
Analysts like Wedbush and Citi have lowered their price targets.
Technical indicators suggest bearish momentum with no strong upward trend.
In Q4 2025, revenue declined by 5.94% YoY to $199.9 million. However, net income improved by 62.16% YoY to -$58.9 million, and EPS increased by 62.07% YoY to -$0.47. Gross margin also improved to 85.13%, up 5.38% YoY.
Analysts are mixed on APLS. H.C. Wainwright and Citi maintain Buy ratings with price targets of $48 and $44, respectively, citing optimism about Syfovre and Empaveli. However, Wedbush and Wells Fargo have lowered their price targets, citing flat pricing and slower-than-expected growth in certain product lines.
